ClinicalTrials.gg
CompletedNCT01568294Updated Nov 12, 2019

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

A Phase 1 interventional study of pomalidomide in Multiple Myeloma, sponsored by Celgene. Completed at 8 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 102 studies testing pomalidomide in Multiple Myeloma — 15 open to participants now, 39 under way, 9 of them phase 3. pomalidomide · Multiple Myeloma.

Enrollment
81st of 102
12 · median 50
Started
2012
with 6 others
Phase 1
6 of 102
none open now
Registered
15th of 102
by date
Lead sponsor
10 of 102
Celgene

Among the 102 studies testing pomalidomide in Multiple Myeloma, this one is the 81st largest by enrollment, is one of 7 that started in 2012, is one of 6 in phase 1, and was the 15th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

15 of the 102 studies testing pomalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About pomalidomide

pomalidomide: first FDA approval 2013 (POMALYST), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies testing pomalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to determine the tolerated dose of pomalidomide and also to evaluate the pharmacokinetics, safety and efficacy of pomalidomide in patients with refractory or relapsed and refractory multiple myeloma.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be ≥ 20 years of age at the time of signing the document
  • The subject must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted.
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Subjects must have documented diagnosis of multiple myeloma and have
  • All subjects must have had at least 2 prior lines of anti-myeloma therapy. Induction therapy followed by stem cell transplant and consolidation/maintenance will be considered as one line
  • All subjects must have either or relapsed and refractory disease defined as documented disease progression during or within 60 days of completing their last anti-myeloma therapy.

    • Primary refractory: Subjects who have never achieved any response better than progressive disease (PD) to any previous line of anti-myeloma therapy.
    • Relapsed and refractory: Subjects who have relapsed after having achieved at least stable disease (SD) to at least one prior regimen and then developed progressive disease (PD) on or within 60 days of completing their last anti-myeloma therapy.
  • Subjects must have also undergone prior treatment with at least 2 cycles of lenalidomide and at least 2 cycles of bortezomib (either in separate regimens or within the same regimen).
  • All subjects must have received adequate prior alkylator therapy.
  • (ECOG) performance status score of 0, 1, or 2.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females
  • to thalidomide, lenalidomide, or dexamethasone
  • ≥ Grade 3 rash during prior thalidomide or lenalidomide therapy
  • Patients unable or unwilling to undergo antithrombotic prophylactic treatment will not be eligible to participate in this study
  • Any of the following laboratory abnormalities:

    • (ANC) \< 1,000/µL
    • count \< 75,000/µL for patients in whom \< 50% of bone marrow nucleated cells are plasma cells; or a platelet count \< 30,000/µL for patients in whom ≥ 50% of bone marrow nucleated cells are plasma cells
    • \< 45 mL/min according to Cockcroft-Gault formula
    • Corrected serum calcium > 14 mg/dL (> 3.5 mmol/L)
    • \< 8 g/dL (\< 4.9 mmol/L; prior RBC transfusion or recombinant human erythropoietin use is permitted)
    • Serum glutamic oxaloacetic transaminase () /aspartate aminotransferase (AST) or serum glutamic pyruvic transaminase (SGPT) /alanine aminotransferase (ALT) > 3.0 x (ULN)
    • Serum total > 2.0 mg/dL (34.2 μmol/L); or ≥ 3.0 x upper limit of normal (ULN) for subjects with hereditary benign hyperbilirubinaemia
  • Peripheral neuropathy ≥ Grade 2
  • Patients who received any of the following within the last 14 days of initiation of study treatment:

    • Plasmapheresis
    • Major surgery (kyphoplasty is not considered major surgery)
    • Radiation therapy
    • Use of any anti-myeloma drug therapy
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    pomalidomide

    Patients will receive pomalidomide orally on Days 1-21 of each 28-day cycle until when/if a discontinuation criterion, e.g., disease progression, development of an unacceptable toxicity, voluntary withdrawal, or pomalidomide is in market for the target indication.

    Drug: pomalidomide

Interventions

  • 2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events

    Incidence of dose-limiting toxicity in accordance with Common Terminology Criteria for Adverse Events

    Time frame: Up to 28 Days

Secondary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Maximum observed plasma concentration (Cmax)

    Time frame: Up to 28 days

  2. Time to maximum observed plasma concentration (tmax)

    Time to maximum observed plasma concentration (tmax)

    Time frame: Up 28 days

  3. Area under the plasma concentration-time curve (AUC0-t)

    Area under the plasma concentration-time curve (AUC0-t)

    Time frame: Up to 28 days

  4. Apparent total plasma clearance (CL/F)

    Apparent total plasma clearance (CL/F)

    Time frame: Up to 28 days

  5. Apparent total volume of distribution (Vz/F)

    Apparent total volume of distribution (Vz/F)

    Time frame: Up to 28 days

  6. Estimate of the terminal elimination half-life in plasma (t1/2)

    Estimate of the terminal elimination half-life in plasma (t1/2)

    Time frame: Up to 28 days

  7. Safety (the number of participants with adverse events, incidence, severity, causality)

    Safety (the number of participants with adverse events, incidence, severity, causality)

    Time frame: Up to 2 years

  8. Progression-free survival

    Progression-free survival

    Time frame: Up to 28 days

  9. Myeloma response

    Myeloma response

    Time frame: Up to 28 days

  10. Time to Response

    Time to Response

    Time frame: Up to 28 days

  11. Duration of Response

    Duration of Response

    Time frame: Up to 28 days

07

Study locations

8 sites
  • Nagoya City University Hospital
    Nagoya, Aichi 467-8602, Japan
  • Tokai University Hospital
    Isehara, Kanagawa 259-1193, Japan
  • Saitama Medical Center, Saitama Medical University
    Kawagoe, Saitama 350-8550, Japan
  • National Cancer Center Hospital
    Tyuuou, Tokyo 104-0045, Japan
  • Kyusyu University Hospital
    Fukuoka, 812-8582, Japan
  • Kameda General Hospital
    Kamogawa, 296-1602, Japan
  • Niigata Cancer Center Hospital
    Niigata, 951-8566, Japan
  • Okayama Medical Center
    Okayama, 701-1192, Japan
08

References and documents

Publications

  • Matsue K, Iwasaki H, Chou T, Tobinai K, Sunami K, Ogawa Y, Kurihara M, Midorikawa S, Zaki M, Doerr T, Iida S. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma. Cancer Sci. 2015 Nov;106(11):1561-7. doi: 10.1111/cas.12772. Epub 2015 Nov 4. PubMed 26292221 ↗
  • Mark TM, Forsberg PA, Rossi AC, Pearse RN, Pekle KA, Perry A, Boyer A, Tegnestam L, Jayabalan D, Coleman M, Niesvizky R. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma. Blood Adv. 2019 Feb 26;3(4):603-611. doi: 10.1182/bloodadvances.2018028027. PubMed 30792190 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Jul 2015, 39 months.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's 39 months is close to that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2012
First posted
Apr 2, 2012
StartActual
Apr 1, 2012
Primary completionActual
Jul 8, 2015
CompletionActual
Jul 8, 2015
Last update
Nov 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01568294
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 2, 2012
Start date
Apr 1, 2012
Primary completion
Jul 8, 2015
Completion
Jul 8, 2015
Last update
Nov 12, 2019

Study contacts

Toru Sasaki
study director · Celgene K.K

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion